NeoGenomics Stock Forecast, Price & News

NeoGenomics (NASDAQ:NEO) Frequently Asked Questions

Is NeoGenomics a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NeoGenomics stock.
View analyst ratings for NeoGenomics or view top-rated stocks.

How has NeoGenomics' stock price been impacted by Coronavirus (COVID-19)?

NeoGenomics' stock was trading at $24.78 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NEO shares have increased by 0.6% and is now trading at $24.94.
View which stocks have been most impacted by COVID-19.

When is NeoGenomics' next earnings date?

NeoGenomics is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for NeoGenomics.

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) announced its earnings results on Thursday, November, 4th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.09) by $0.01. The medical research company earned $121.30 million during the quarter, compared to analyst estimates of $125.09 million. NeoGenomics had a negative trailing twelve-month return on equity of 1.33% and a net margin of 10.08%. The business's revenue for the quarter was down 3.3% on a year-over-year basis. During the same period in the prior year, the company earned $0.04 EPS.
View NeoGenomics' earnings history.

What guidance has NeoGenomics issued on next quarter's earnings?

NeoGenomics updated its FY 2021 earnings guidance on Thursday, November, 18th. The company provided earnings per share (EPS) guidance of $-0.290-$-0.250 for the period, compared to the Thomson Reuters consensus estimate of $-0.210. The company issued revenue guidance of $482.50 million-$487.50 million, compared to the consensus revenue estimate of $497.53 million.

What price target have analysts set for NEO?

10 analysts have issued 1-year price objectives for NeoGenomics' stock. Their forecasts range from $41.00 to $65.00. On average, they anticipate NeoGenomics' stock price to reach $51.40 in the next twelve months. This suggests a possible upside of 106.1% from the stock's current price.
View analysts' price targets for NeoGenomics or view top-rated stocks among Wall Street analysts.

Who are NeoGenomics' key executives?

NeoGenomics' management team includes the following people:

• Mark Mallon, Chief Executive Officer & Director
• George A. Cardoza, President & Chief Operating Officer-Lab Operations (LinkedIn Profile)
• Kathryn B. McKenzie, Chief Financial Officer
• Steven A. Ross, Chief Information Officer & Vice President
• John Mooney, Chief Technology Officer

What is Douglas M. VanOort's approval rating as NeoGenomics' CEO?

116 employees have rated NeoGenomics CEO Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among NeoGenomics' employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of NeoGenomics' key competitors?

Some companies that are related to NeoGenomics include Bausch Health Companies (BHC), Amplifon (AMFPF), DaVita (DVA), DENTSPLY SIRONA (XRAY), 10x Genomics (TXG), Demant A/S (WILYY), Smith & Nephew (SN), QIAGEN (QGEN), Henry Schein (HSIC), Valeant Pharmaceuticals International (VRX), Universal Health Services (UHS), GoodRx (GDRX), Repligen (RGEN), Dr. Reddy's Laboratories (RDY) and Teva Pharmaceutical Industries (TEVA).
View all of NEO's competitors.

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Square (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

Who are NeoGenomics' major shareholders?

NeoGenomics' stock is owned by a number of institutional and retail investors. Top institutional investors include Scout Investments Inc. (0.22%), Exchange Traded Concepts LLC (0.09%), State of Alaska Department of Revenue (0.07%) and Crossmark Global Holdings Inc. (0.02%). Company insiders that own NeoGenomics stock include Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lawrence Martin Weiss, Mark Mallon, Oort Douglas M Van, Robert J Shovlin, Steven C Jones and William Bonello.
View institutional ownership trends for NeoGenomics.

Which major investors are selling NeoGenomics stock?

NEO stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc., and State of Alaska Department of Revenue. Company insiders that have sold NeoGenomics company stock in the last year include Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Kathryn B Mckenzie, and Robert J Shovlin.
View insider buying and selling activity for NeoGenomics or view top insider-selling stocks.

Which major investors are buying NeoGenomics stock?

NEO stock was bought by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC, and Crossmark Global Holdings Inc..
View insider buying and selling activity for NeoGenomics or or view top insider-buying stocks.

How do I buy shares of NeoGenomics?

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NeoGenomics' stock price today?

One share of NEO stock can currently be purchased for approximately $24.94.

How much money does NeoGenomics make?

NeoGenomics has a market capitalization of $3.07 billion and generates $444.45 million in revenue each year. The medical research company earns $4.17 million in net income (profit) each year or $0.36 on an earnings per share basis.

How many employees does NeoGenomics have?

NeoGenomics employs 1,700 workers across the globe.

What is NeoGenomics' official website?

The official website for NeoGenomics is www.neogenomics.com.

Where are NeoGenomics' headquarters?

NeoGenomics is headquartered at 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913.

How can I contact NeoGenomics?

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at (239) 768-0600, via email at [email protected], or via fax at 239-690-4237.